A Continued Conversation on the Maternal and Fetal Consequences of Rare Bleeding Disorders

February 3, 2017

To view this Webinar, please scroll down to the bottom of the page.

This is a recorded version of our webinar on the maternal and fetal consequences of rare bleeding disorders, specifically fibrinogen and FXIII disorders, and Glanzmann’s thrombasthenia, presented by Dr. Meera Chitlur and Dr. Madhvi Rajpurkar that took place on February 3, 2017. This webinar was jointly sponsored by the Creighton University Health Sciences Continuing Education program and the Foundation for Women & Girls with Blood Disorders. The production and archiving of this program were made possible in part by an educational grant from Novo Nordisk Inc.  

Program Description: 

This Webinar will provide evidence-based, practical information on the range of maternal and fetal consequences of rare bleeding disorders and the increased risk of bleeding complications particularly during the postpartum period. It will also inform medical providers on the new therapeutics available and their appropriate application to the challenges of treating these rare bleeding disorders. 

Learning Objectives: 

After completing this educational activity and the post-test, participants should be able to: 

Program Faculty
Meera Chitlur, MD
Barnhart-Lusher Hemostasis Research Endowed Chair
Director, Hemophilia Treatment Center/Hemostasis Program & Special Coagulation Laboratory
Professor of Pediatrics
Wayne State University School of Medicine
Division of Hematology/Oncology
Children’s Hospital of Michigan

Madhavi Rajpurkar, MD
Division Chief, Hematology 
Professor of Pediatrics
Director, Pediatric Thrombosis Program
Wayne State University
Division of Hematology/Oncology
Children’s Hospital of Michigan